Sunday, August 2, 2015

M&A in the pharma air

Reports say that Roche is trying to buy Illumina and Bristol-Myers Squibb is trying to buy Amylin.

M&A in the pharma air


The mergers-and-acquisitions market has been slow for the last couple years, but two possible mergers are in the pharmaceutical air.

Actually, as colleague Mike Armstrong always notes, there are no mergers. One company buys another and gets to make the rules.

Anyway, multiple reports says that Roche is trying to buy Illumina and Bristol-Myers Squibb is trying to buy Amylin.

Roche has facilities in the North Jersey towns of Nutley and Branchburg.

Bristol-Myers Squibb, whose top selling drug is Plavix ($7.1 billion in 2011), has five New Jersey locations: Hopewell, Nassau Park, New Brunswick, Plainsboro and Princeton.

Amylin and Illumina are both based in San Diego.

The Financial Times reported that Swiss-based Roche raised its cash offer for Illumina by 15 percent to $51 a share, valuing Illumina at about $6.7 billion.

“Based on our discussions with Illumina shareholders we have seen interest to accelerate the takeover process,” said Severin Schwan, Roche’s chief executive, according to the Financial Times.

Bloomberg reported that Bristol-Myers Squibb made an unsolicited bid of $3.5 billion for Amylin. Thus far, it has not been accepted. Indeed, Bloomberg suggested it might spur others to bid.

We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at

David Sell
Also on
letter icon Newsletter